News Article and Medical Journal

The following article describes Impaired Renal Function Pathophysiology and Lipid Lowering Therapy in conjunction with dyslipidemia and renal disease. It summarizes the abnormalities in lipid metabolism associated with renal disease as well as therapeutic procedures for lipid lowering in patients with impaired renal function.

You will find sections such as Lipoprotein metabolism and renal disease, Lipoproteins and glomerular dysfunction, Lipid lowering therapy in patients with impaired renal function (Bile acid binding resins, Statins, Fibrates, Nicotinic acid derivatives, and Lipid apheresis).

Read completely about Impaired Renal Function Pathophysiology in Dyslipidemia, here (source: kup.at/jcbc)

An endocrine disorder which is characterized by a deficiency in parathyroid hormon (PTH), then resulting in hypocalcemia and hyperphospatemia. The following are Differential Diagnosis of Hypocalcemia in the Pathophysiology of Hipothyroidism:

1.  Hypoalbuminemia
2.  Renal Failure 
3.  Acute Pancreatitis 
4.  Puerpural Tetany (eclampsia) 
5.  Ethylene glycol toxicosis 
6.  Phosphate enemas 
7.  Use of EDTA anticoagulant 
8.  Hypomagnesemia  
9.  Nutritional secondary hyperparathyroidism 
10.  Laboratory error 
11.  Malabsorption syndrome 
12.  Transfusion with citrated blood  
13.  Bone tumors 
14.  Soft tissue trauma 
15.  Vitamin D deficiency

Differential Diagnosis of Hypocalcemia in the Pathophysiology of Hipothyroidism continued »

The following algorithm diagram shows a simplified approach of Insulin Therapy Initiation for Type II Diabetes Mellitus. This treatment guide was issued by Texas Diabetes Council and has been revised on 1/27/10.

Insulin Therapy Initiation Algorithm Guide for Type II Diabetes continued »

The European Medicines Agency (EMEA), European CDC, and the Heads of Medicines Agencies (HMA) established a document regarding the monitoring of the benefits and risks of H1N1 vacines in relation to the safety and effectivenes of the vaccines.

The document covers materials such as Influenza A (H1N1) vaccines safety and effectiveness, the immunogenicity, benefit-risk evaluation, vaccine manufacturers, the vaccines authorised, research, clinical and public health centres, components of strategies in monitoring the benefit-risk  A/H1N1 vaccines, and the funding mechanisms in relation to the overall benefit-risk assesment.

Influenza A (H1N1) Vaccine Risk-Benefit Monitoring in Europe continued »